Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A single-nucleotide polymorphism of the Fcγ receptor type IIIA gene in the recipient predicts transplant outcomes after HLA fully matched unrelated BMT for myeloid malignancies.
Takami A, Espinoza JL, Onizuka M, Ishiyama K, Kawase T, Kanda Y, Sao H, Akiyama H, Miyamura K, Okamoto S, Inoue M, Ohtake S, Fukuda T, Morishima Y, Kodera Y, Nakao S; Japan Marrow Donor Program. Takami A, et al. Among authors: okamoto s. Bone Marrow Transplant. 2011 Feb;46(2):238-43. doi: 10.1038/bmt.2010.88. Epub 2010 Apr 19. Bone Marrow Transplant. 2011. PMID: 20400988
Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease.
Yanada M, Naoe T, Iida H, Sakamaki H, Sakura T, Kanamori H, Kodera Y, Okamoto S, Kanda Y, Sao H, Asai O, Nakai K, Maruta A, Kishi K, Furukawa T, Atsuta Y, Yamamoto K, Tanaka J, Takahashi S. Yanada M, et al. Among authors: okamoto s. Bone Marrow Transplant. 2005 Nov;36(10):867-72. doi: 10.1038/sj.bmt.1705148. Bone Marrow Transplant. 2005. PMID: 16113659
Disease stage stratified effects of cell dose in unrelated BMT for hematological malignancies: a report from Japan Marrow Donor Program.
Inamoto Y, Miyamura K, Okamoto S, Akiyama H, Iida H, Eto T, Morishima Y, Kawa K, Kikuchi A, Nagatoshi Y, Tanaka J, Ashida T, Hirokawa M, Tsuchida M, Mori S. Inamoto Y, et al. Among authors: okamoto s. Bone Marrow Transplant. 2011 Sep;46(9):1192-202. doi: 10.1038/bmt.2010.281. Epub 2010 Nov 8. Bone Marrow Transplant. 2011. PMID: 21057551
A single nucleotide polymorphism of IL-17 gene in the recipient is associated with acute GVHD after HLA-matched unrelated BMT.
Espinoza JL, Takami A, Onizuka M, Kawase T, Sao H, Akiyama H, Miyamura K, Okamoto S, Inoue M, Ohtake S, Fukuda T, Morishima Y, Kodera Y, Nakao S; Japan Marrow Donor Program. Espinoza JL, et al. Among authors: okamoto s. Bone Marrow Transplant. 2011 Nov;46(11):1455-63. doi: 10.1038/bmt.2010.325. Epub 2011 Jan 10. Bone Marrow Transplant. 2011. PMID: 21217785
M-CSF attenuates severity of chronic GVHD after unrelated BMT.
Kimura F, Sato K, Akiyama H, Sao H, Okamoto S, Kobayashi N, Hara M, Kawa K, Motoyoshi K; Japan Marrow Donor Program. Kimura F, et al. Among authors: okamoto s. Bone Marrow Transplant. 2012 Mar;47(3):426-9. doi: 10.1038/bmt.2011.90. Epub 2011 Apr 18. Bone Marrow Transplant. 2012. PMID: 21499320
Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia.
Atsuta Y, Suzuki R, Nagamura-Inoue T, Taniguchi S, Takahashi S, Kai S, Sakamaki H, Kouzai Y, Kasai M, Fukuda T, Azuma H, Takanashi M, Okamoto S, Tsuchida M, Kawa K, Morishima Y, Kodera Y, Kato S; Japan Cord Blood Bank Network. Atsuta Y, et al. Among authors: okamoto s. Blood. 2009 Feb 19;113(8):1631-8. doi: 10.1182/blood-2008-03-147041. Epub 2008 Dec 22. Blood. 2009. PMID: 19104080 Free article. Clinical Trial.
Analysis of 500 bone marrow transplants from unrelated donors (UR-BMT) facilitated by the Japan Marrow Donor Program: confirmation of UR-BMT as a standard therapy for patients with leukemia and aplastic anemia.
Kodera Y, Morishima Y, Kato S, Akiyama Y, Sao H, Matsuyama T, Kawa K, Sakamaki H, Nakagawa S, Hirabayashi N, Dohi H, Okamoto S, Hiraoka A, Gondo H, Tsuchida M, O H, Harada M, Asano S, Juji T, Sasazuki T, Takaku F. Kodera Y, et al. Among authors: okamoto s. Bone Marrow Transplant. 1999 Nov;24(9):995-1003. doi: 10.1038/sj.bmt.1702027. Bone Marrow Transplant. 1999. PMID: 10556959
Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation.
Hiraoka A, Ohashi Y, Okamoto S, Moriyama Y, Nagao T, Kodera Y, Kanamaru A, Dohy H, Masaoka T; Japanese FK506 BMT(Bone Marrow Transplantation) Study Group. Hiraoka A, et al. Among authors: okamoto s. Bone Marrow Transplant. 2001 Jul;28(2):181-5. doi: 10.1038/sj.bmt.1703097. Bone Marrow Transplant. 2001. PMID: 11509936 Clinical Trial.
Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan.
Yanada M, Emi N, Naoe T, Sakamaki H, Takahashi S, Hirabayashi N, Hiraoka A, Kanda Y, Tanosaki R, Okamoto S, Iwato K, Atsuta Y, Hamajima N, Tanimoto M, Kato S. Yanada M, et al. Among authors: okamoto s. Bone Marrow Transplant. 2004 Aug;34(4):331-7. doi: 10.1038/sj.bmt.1704596. Bone Marrow Transplant. 2004. PMID: 15220958
Busulfex (i.v. BU) and CY regimen before SCT: Japanese-targeted phase II pharmacokinetics combined study.
Kim SW, Mori SI, Tanosaki R, Fukuda T, Kami M, Sakamaki H, Yamashita T, Kodera Y, Terakura S, Taniguchi S, Miyakoshi S, Usui N, Yano S, Kawano Y, Nagatoshi Y, Harada M, Morishima Y, Okamoto S, Saito AM, Ohashi Y, Ueda R, Takaue Y. Kim SW, et al. Among authors: okamoto s. Bone Marrow Transplant. 2009 Apr;43(8):611-7. doi: 10.1038/bmt.2008.372. Epub 2008 Nov 17. Bone Marrow Transplant. 2009. PMID: 19011665 Clinical Trial.
3,160 results